Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5919
Abstract: BACKGROUND The development of immune-related adverse events (irAEs) may be associated with clinical efficacy of checkpoint inhibitors (CPIs) in patients with cancer. We therefore investigated the effect of irAEs and pre-treatment parameters on outcome in… read more here.
Keywords: eosinophil count; immune related; tumour entities; pre treatment ... See more keywords
Single-centre survival analysis over 10Â years after MR-guided radiofrequency ablation of liver metastases from different tumour entities
Sign Up to like & getrecommendations! Published in 2022 at "Insights into Imaging"
DOI: 10.1186/s13244-022-01178-8
Abstract: Background Radiofrequency ablation (RFA) is a minimal-invasive, local therapy in patients with circumscribed metastatic disease. Although widely used, long time survival analysis of treated liver metastases is still pending while also analysing the patients’ experience… read more here.
Keywords: analysis; radiofrequency; liver metastases; tumour entities ... See more keywords